Product Pathways - Tyrosine Kinase / Adaptors
HER2/ErbB2 (29D8) Rabbit mAb #2165
|2165S||100 µl (10 western blots)||---||In Stock||---|
|2165||carrier free and custom formulation / quantity||email request|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IP=Immunoprecipitation, IHC-P=Immunohistochemistry (Paraffin), IHC-F=Immunohistochemistry (Frozen), IF-IC=Immunofluorescence (Immunocytochemistry), F=Flow Cytometry
Species predicted to react based on 100% sequence homology: Mouse, Rat.
* Product-specific protocol.
Specificity / Sensitivity
HER2/ErbB2 (29D8) Rabbit mAb detects endogenous levels of total ErbB2 protein. This antibody does not cross-react with related kinases.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding tyrosine 1248 of human ErbB2 protein.
Western blot analysis of cell extracts from various cell lines, using HER2/ErbB2 (29D8) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using HER2/ErbB2 (29D8) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human breast carcinoma using HER2/ErbB2 (29D8) RmAb in the presence of control peptide (left) or HER2/ErbB2 Blocking Peptide #1059 (right).
Immunohistochemical analysis of paraffin-embedded SKBr3 (high HER2) (left), MDA-MB-453 (moderate HER2) (middle) and MDA-MB-468 (low HER2) (right), using HER2/ErbB2 (29D8) Rabbit mAb.
Immunohistochemical analysis of frozen SKOV-3 xenograft using HER2/ErbB2 (29D8) Rabbit mAb.
Flow cytometric analysis of MCF7 cells using HER2/ErbB2 (29D8) Rabbit mAb (blue) compared to a nonspecific negative control antibody (red).
The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity (1). While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members (2). Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers (3). Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase (4). ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy. Phosphorylation of the kinase domain residue Tyr877 of ErbB2 (homologous to Tyr416 of pp60c-Src) may be involved in regulating ErbB2 biological activity. The major autophosphorylation sites in ErbB2 are Tyr1248 and Tyr1221/1222; phosphorylation of these sites couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway (1,5).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 8112 SignalStain® Antibody Diluent
- 8117 SignalSlide® Phospho-ErbB Family IHC Controls
- 9923 Phospho-HER2/ErbB2 Antibody Sampler Kit
- 1059 HER2/ErbB2 Blocking Peptide
- 2243 Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb
- 2248 HER2/ErbB2 (44E7) Mouse mAb
- 2241 Phospho-HER2/ErbB2 (Tyr877) Antibody
- 2242 HER2/ErbB2 Antibody
- 2244 Phospho-HER2/ErbB2 (Tyr1248)/EGFR (Tyr1173) Antibody
- 2247 Phospho-HER2/ErbB2 (Tyr1248) Antibody
- 2249 Phospho-HER2/ErbB2 (Tyr1221/1222) Antibody
- 3250 HER2/ErbB2 (M45) Antibody
- 7071 Phototope®-HRP Western Blot Detection System, Anti-rabbit IgG, HRP-linked Antibody
- 7074 Anti-rabbit IgG, HRP-linked Antibody
- 7720 Prestained Protein Marker, Broad Range (Premixed Format)
- 7727 Biotinylated Protein Ladder Detection Pack
- 7003 20X LumiGLO® Reagent and 20X Peroxide
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
DRAQ5® is a registered trademark of Biostatus Limited.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
This antibody is developed, validated, and produced by CST using in part technology under license (granting certain rights including those under U.S. Patents No. 5,675,063 and 7,429,487) from Epitomics, Inc.